Scholar Rock Holding (SRRK) Profit After Tax (2017 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Profit After Tax of -$105.5 million for Q1 2026, down 41.2% year-over-year from -$179.4 million in Q1 2025, and down 458639.13% quarter-over-quarter from -$23000.0 in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Profit After Tax (2017 - 2026) Analysis & Trends
Scholar Rock Holding's Profit After Tax history runs 10 years deep, the most recent figure standing at -$105.5 million for Q1 2026.
- In Q1 2026, Profit After Tax fell 41.2% year-over-year to -$105.5 million; the TTM figure through Mar 2026 stood at -$317.7 million (down 60.73% YoY), while the FY2025 annual figure was -$66000.0, down 197.06% from the prior year.
- Profit After Tax for Q1 2026 stood at -$105.5 million, down from -$23000.0 in the prior quarter.
- The five-year high for Profit After Tax was $32000.0 in Q4 2024, with the low at -$110.0 million in Q2 2025.
- The 5-year median for Profit After Tax is -$44.0 million (2022), against an average of -$51.4 million.
- The sharpest annual moves came in 2023 and 2024: Profit After Tax tumbled 395.33% in 2023, then jumped 100.07% in 2024.
- Scholar Rock Holding's Profit After Tax stood at -$39.2 million in 2022, then declined by 19.86% to -$47.0 million in 2023, then surged by 100.07% to $32000.0 in 2024, then plunged by 171.88% to -$23000.0 in 2025, then slumped by 458639.13% to -$105.5 million in 2026.
- Business Quant data shows SRRK's Profit After Tax at -$105.5 million in Q1 2026, -$23000.0 in Q4 2025, and -$102.2 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Scholar Rock Holding | 7.21 Bn | 7.21 Bn | - | -109.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -109.90 Mn |
| Mar 31, 2026 | -105.51 Mn |
| Dec 31, 2025 | -90.99 Mn |
| Sep 30, 2025 | -102.22 Mn |
| Jun 30, 2025 | -110.10 Mn |
| Mar 31, 2025 | -74.72 Mn |
| Dec 31, 2024 | -66.45 Mn |
| Sep 30, 2024 | -64.48 Mn |
| Jun 30, 2024 | -58.51 Mn |
| Mar 31, 2024 | -56.85 Mn |
| Dec 31, 2023 | -46.09 Mn |
| Sep 30, 2023 | -42.36 Mn |
| Jun 30, 2023 | -37.93 Mn |
| Mar 31, 2023 | -39.38 Mn |
| Dec 31, 2022 | -39.20 Mn |
| Sep 30, 2022 | -44.15 Mn |
| Jun 30, 2022 | -44.00 Mn |
| Mar 31, 2022 | -7.95 Mn |
| Dec 31, 2021 | -35.95 Mn |
| Sep 30, 2021 | -37.52 Mn |